5 Stocks That Fell Every Day Last Week

Some stocks take a pounding, but there's usually what they call a dead-cat bounce. Even if a stock's inevitable path is to head lower, there's usually a respite in the downticks.

It doesn't always pan out that way.

Last week was rather uneventful for the market. The Dow 30, Nasdaq, and S&P 500 all closed lower, but none of the market gauges shed more than 0.2% of their value.

Some stocks weren't that lucky. More than a few actively traded companies fell every single trading day last week, and more often than not it happened without any material news. Investors just decided to move on, and the small daily downticks added up to double-digit percentage share-price declines.

Let's take a closer look at five of the companies that saw their share prices drop in each of this past week's five trading days.

Company

Mar. 22

Weekly Loss

JDS Uniphase (NASDAQ: JDSU  )

$13.47

(12%)

Nabors Industries (NYSE: NBR  )

$15.41

(11%)

Ariad Pharmaceuticals (NASDAQ: ARIA  )

$19.38

(11%)

Dendreon (NASDAQ: DNDN  )

$4.89

(10%)

Amarin Pharmaceuticals (NASDAQ: AMRN  )

$7.63

(10%)

Source: Barron's.

JDS Uniphase offered product updates during the Optical Fiber Communication Conference/National Fiber Optic Engineers Conference during the week. The optical networking specialist announced the availability of several new items. It wasn't enough. Even though JDS Uniphase is still growing -- analysts see marginal upticks in revenue and profitability for the fiscal year ending in June -- investors were still set on rotating out of a company that had hit a fresh 52-week high last month.

Nabors Industries slipped despite an analyst upgrade. Zacks Equity Research is boosting its rating on Nabors from underperform to neutral, encouraged in part by the onshore contractor's recent decision to start paying quarterly dividends. Then again, it's not as if a hold rating is something to scrapbook.

Ariad Pharmaceuticals had good news on Friday, as the European equivalent of the FDA approved the company's chronic myeloid leukemia (CML) drug Iclusig. One can argue that the market was already banking on approval, but is that any excuse for Ariad to close lower every single day last week?

Dendreon is another biotech that slumped on the week. The company kicked off the week by announcing that it had agreed to settle a securities class action lawsuit. It also presented at the 25th Annual ROTH Conference in California. These are typically events that push a stock higher. Settling complaints stemming from accusations that company executives made misleading statements a couple of years ago eliminates the uncertainty of the lawsuit's financial obligations. Presenting at an analyst conference gives a company the opportunity to shine as it presents its bullish scenario. However, those events weren't enough to keep sellers from moving on.

Finally, we have Amarin losing weight. The pharmaceutical stock got panned by Jim Cramer on Mad Money. "We're going to veto it," Cramer offered during Thursday's Lightning Round segment. He compared it to the New York Mets without R.A. Dickey, the Cy Young winner that the team inexplicably traded late last year.

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners?

With so much of the financial industry getting bad press these days, it may be a "be greedy when others are fearful" moment. Not surprisingly, some of Warren Buffett's biggest investments are in the space. In the Motley Fool's free report, "The Stocks Only the Smartest Investors Are Buying," you can learn about a small, under-the-radar bank that's too tiny for Buffett's billions. Too bad, because it has better operating metrics than his favorites. Just click here to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2329396, ~/Articles/ArticleHandler.aspx, 10/25/2014 12:00:12 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 14 hours ago Sponsored by:
DOW 16,805.41 127.51 0.76%
S&P 500 1,964.58 13.76 0.71%
NASD 4,483.72 30.92 0.69%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2014 3:59 PM
AMRN $0.94 Down -0.11 -10.48%
Amarin Corp plc (A… CAPS Rating: ****
ARIA $5.83 Up +0.12 +2.10%
Ariad Pharmaceutic… CAPS Rating: ***
DNDN $1.03 Down -0.01 -0.96%
Dendreon Corp CAPS Rating: **
JDSU $12.10 Down -0.31 -2.50%
JDS Uniphase Corp CAPS Rating: ***
NBR $18.73 Down -0.26 -1.37%
Nabors Industries… CAPS Rating: ***

Advertisement